• Blog
  • Cancer Immunotherapy Market Forecast | 2022-28

    Cancer Immunotherapy Market Forecast | 2022-28

    Cancer Immunotherapy Market Forecast | 2022-28
    Report code - SR1999 Delivery - 2 Weeks
    Get Free Sample |
    Cancer Immunotherapy Market Size, Share, Trend, Forecast, Competitive Analysis, and Growth See more...

    Market Insights

    The global cancer immunotherapy market was estimated at USD 118.9 Billion in 2021 and is likely to grow at a CAGR of 12.48% from 2022-2028 to reach USD 273.32 Billion in 2028.

    Wish to get a free sample? Register here. 

    What is cancer immunotherapy?

    Cancer immunotherapy, also known as immuno-oncology, is a cancer treatment that uses a person’s immune system to prevent, control, and fight cancer. Cancer immunotherapy is a type of biological therapy, that uses substances made from living organisms to boost the immune system in order to eradicate cancer.

    Drivers

    • The growing adoption of target therapy rising cancer incidence, and technological advancements in cancer treatment therapies.
    • Rising R&D activities in the field of cancer immunotherapy.
    • An increase in the adoption of immunotherapy over other treatment options.

    To learn more about this report, request a free sample here.

    Compared to immunotherapies, cancer treatment alternatives including chemotherapy and radiation therapy are more frequently employed despite having higher negative effects. The former is based on the elimination of cancer cells through surgery, chemotherapy, or radiation. These treatments can efficiently kill or eliminate cancer cells, but their use is frequently limited since they also frequently kill significant numbers of healthy cells. Immunotherapies are preferred above other treatment alternatives because they work by boosting the body's natural defenses with the help of synthetic proteins like monoclonal antibodies.

    Key Players

    The following are some of the key players in the market:

    • Amgen Inc.
    • AstraZeneca plc
    • Bayer AG
    • Bristol-Myers Squibb Co.
    • ELI Lilly and Company
    • F Hoffman-La Roche Ltd.
    • Janssen Global Services, LLC (Johnson and Johnson)
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc

    Segment Analysis

    Want to know the most attractive market segments? Register here.

    By Drug Type

    The market is bifurcated into monoclonal antibodies, cancer vaccines, checkpoint inhibitors, cell therapies, immunomodulators, and interferons alpha.

    Monoclonal antibodies held the major share of the market in 2021, and are expected to remain the biggest demand generator for the cancer immunotherapy market in the foreseen future. Key factors such as cost-effectiveness and increasing investments in the R&D of monoclonal antibodies are expected to drive market growth in the coming years.

    By Diagnosis Type

    The market is segmented as lung cancer, breast cancer, multiple myeloma, colorectal cancer, head & neck cancer, prostate cancer, melanoma, and other cancer types.

    Lung cancer captured the largest share of the cancer immunotherapy market in 2021, due to factors such as the increasing number of patients suffering from lung diseases. The segment is likely to remain dominant during the forecast period, owing to the growing awareness of the early therapeutics of lung cancer.

    By End-User Type

    The market is segmented into hospitals, clinics, and others. Among these end-user types, hospital dominates the market and is expected to grow with the highest CAGR during the forecast period. Hospitals are highly preferred for cancer immunotherapy, and the rising demand for cancer immunotherapy in hospitals is expected to drive market growth over the forecast period.

    Regional Analysis

    North America is expected to remain the largest market for cancer immunotherapy over the forecast period. Major factors such as the rising incidence of cancer, increasing demand for modern cancer therapeutics, and growing geriatric population are fuelling the growth of the regional cancer immunotherapy market. 

    Know which region offers the best growth opportunities. Register here.

    The market is segmented into the following categories:

     Report – Features

    Market Segmentation

    4

    Regions Covered

    4

    Countries/Sub-Regions Covered

    17

    No. of Figures & Tables

    >150

    Company Profiles

    10

    By Drugs Class Type

    • Monoclonal Antibodies 
    • Cancer Vaccines 
    • Checkpoint Inhibitors 
    • Cell Therapies 
    • Immunomodulators 
    • Interferons Alpha 

    By Diagnosis Type

    • Lung Cancer 
    • Breast Cancer 
    • Multiple Myeloma 
    • Colorectal Cancer 
    • Head & Neck Cancer 
    • Prostate Cancer 
    • Melanoma 
    • Other Cancer Types 

    By End-User Type

    • Hospitals 
    • Clinics 
    • Others 

    By Region

    • North America (Country Analysis: The USA, Canada, and Mexico)
    • Europe (Country Analysis: Germany, France, The UK, Russia, Italy, and the Rest of Europe)
    • Asia-Pacific (Country Analysis: China, Japan, India, South Korea, and the Rest of Asia-Pacific)
    • Rest of the World (Country Analysis: Brazil, Argentina, and Others)

    Research Methodology

    This strategic assessment report, from Stratview Research, provides a comprehensive analysis that reflects today’s market realities and future market possibilities for the forecast period of 2022 to 2027.

    The report segments and analyzes the market in the most detailed manner to provide a panoramic view of the market.

    The vital data/information provided in the report can play a crucial role for the market participants and investors in identifying the low-hanging fruits available in the market and formulating the growth strategies to expedite their growth process.

    This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.

    More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data.

    We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

    Report Features

    This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

    Global Cancer Immunotherapy Market Features

    Market Size in 2028

    USD 273.32 billion

     

    Market Size in 2021

    USD118.9 billion

     

    Market Growth (2022-2028)

    12.48% CAGR

     

    Base Year of Study

    2021

     

    Trend Period

    2016-2020

     

    Forecast Period

    2022-2028

     

    Segments Covered

    By End-User Type (Hospitals, Clinics, and Others),

    By Drugs Class Type (Monoclonal Antibodies, Cancer Vaccines, Checkpoint Inhibitors, Cell Therapies, Immunomodulators, and Interferons Alpha),

    By Diagnosis Type (Lung Cancer, Breast Cancer, Multiple Myeloma, Colorectal Cancer, Head & Neck Cancer, Prostate Cancer, Melanoma, and Other Cancer Types),

    By Region (North America [The USA, Canada, and Mexico], Europe [Germany, France, The UK, Russia, Italy, and the Rest of Europe], Asia-Pacific [China, Japan, India, South Korea, and the Rest of Asia-Pacific], and Rest of the World [Brazil, Argentina, and Others].

     

    Top Companies in 2022

    • Amgen Inc.
    • AstraZeneca plc
    • Bayer AG
    • Bristol-Myers Squibb Co.
    • ELI Lilly and Company
    • F Hoffman-La Roche Ltd.
    • Janssen Global Services, LLC (Johnson and Johnson)
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc

     

    Dominant Region

    North America is expected to remain the largest market over the forecast period.

     

    The following are the key features of the report:

    • Overview, industry life cycle analysis, supply chain analysis.
    • Environment analysis: Growth drivers and constraints, Porter’s five forces analysis, SWOT analysis.
    • Trend and forecast analysis.
    • Segment trend and forecast.
    • Competitive landscape and dynamics: Market share, Product portfolio, New Product Launches, etc.
    • Attractive market segments and associated growth opportunities.
    • Emerging trends.
    • Strategic growth opportunities for the existing and new players.
    • Key success factors.

    Customization Options

    With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

    Company Profiling

    • Detailed profiling of additional market players (up to three players)
    • SWOT analysis of key players (up to three players)

    Competitive Benchmarking

    • Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances

    Custom Research: Stratview research offers custom research services across the sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@Stratviewresearch.com

    Frequently Asked Questions (FAQs)

    Cancer immunotherapy, also known as immuno-oncology, is a cancer treatment that uses a persons immune system to prevent, control, and fight cancer. Cancer immunotherapy is a type of biological therapy, that uses substances made from living organisms to boost the immune system in order to eradicate cancer.

    Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Co., ELI Lilly and Company, F Hoffman-La Roche Ltd., Janssen Global Services, LLC (Johnson and Johnson), Merck & Co., Inc., Novartis AG, and Pfizer Inc. are some of the key players in the market.

    North America is estimated to be the dominant market in the coming years.

    The growing adoption of target therapy rising cancer incidence, and technological advancements in cancer treatment therapies. Rising R&D activities in the field of cancer immunotherapy. An increase in the adoption of immunotherapy over other treatment options.

    Cancer Immunotherapy Market was estimated to grow at a CAGR of 12.48% from 2022-2028.

    The study period of this market report is 2016-28.

    Hospital is likely to maintain its dominance in the market in the next five years.

    The global cancer immunotherapy market was estimated at USD 118.9 Billion in 2021 and is likely to reach USD 273.32 Billion in 2028.